Replies to post #8466 on Amarin Corp Plc (AMRN)

[yoyo88]

BioBill, you are a scholar and a gentleman.

It sounds like they have a lot chemically in common (obviously) yet several vital aspects are different. V is a prodrug, V has in vivo superiority, V is a synthesized derivative vs L's EPA being in a more "natural" state for lack of a better word, and the structural differences that you have pointed out today. Not to mention the fact that L's active agent was not well-defined at the time of their NCE status... and of course the MAPP changes which seem to denote a shift toward favoritism of "exceptional" improvements and innovation, despite the known similarities.

Still, to a layman like myself, with all the confusion surrounding this, it seems like a big gray area.

I just want it all behind us so the company and shareholders can move on to whatever the next step may be. Despite what everyone (rightfully) says about NCE not mattering when V is surrounded by the patent fortress, the truth is the overhang does matter when it comes to management's decisions with regard to their commercialization path.

Thanks again BB.